Moore N, Verdoux H, Fantino B (2005). "Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder". International Clinical Psychopharmacology 20 (3): 131–137. doi:10.1097/00004850-200505000-00002. PMID15812262.
Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M (2006). "A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients". Current Medical Research and Opinion 22 (7): 1331–41. doi:10.1185/030079906X115513. PMID16834832.
Lam RW, Andersen HF, Wade AG (July 2008). "Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials". Int Clin Psychopharmacol 23 (4): 181–87. doi:10.1097/YIC.0b013e3282ffdedc. PMID18545055.
Bielski RJ, Ventura D, Chang CC (2004). "A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder". The Journal of Clinical Psychiatry 65 (9): 1190–96. PMID15367045
Ventura D, Armstrong EP, Skrepnek GH, Haim Erder M (2007). "Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial". Current Medical Research and Opinion 23 (2): 245–50. doi:10.1185/030079906X167273. PMID17288677.
Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C (2004). "Escitalopram versus citalopram: the surprising role of the R-enantiomer". Psychopharmacology (Berl.) 174 (2): 163–76. doi:10.1007/s00213-004-1865-z. PMID15160261
Chen F, Larsen MB, Sánchez C, Wiborg O (2005). "The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors". European Neuropsychopharmacology 15 (2): 193–198. doi:10.1016/j.euroneuro.2004.08.008. PMID15695064.
Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjeri N (2007). "Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies". The International Journal of Neuropsychopharmacology 10 (1): 31–40. doi:10.1017/S1461145705006462. PMID16448580.
Clayton A, Keller A, McGarvey EL (2006). "Burden of phase-specific sexual dysfunction with SSRIs". Journal of Affective Disorders 91 (1): 27–32. doi:10.1016/j.jad.2005.12.007. PMID16430968.
Baldwin DS, Reines EH, Guiton C, Weiller E (2007). "Escitalopram therapy for major depression and anxiety disorders". Ann Pharmacother 41 (10): 1583–92. doi:10.1345/aph.1K089. PMID17848424.
Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM (2007). "Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder". Curr Med Res Opin 23: 1303. doi:10.1185/030079907X188107. PMID17559729.
Davidson JR, Bose A, Wang Q (2005). "Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder". J Clin Psychiatry 66 (11): 1441–6. PMID16420082.
Kasper S, Lemming OM, de Swart H (2006). "Escitalopram in the long-term treatment of major depressive disorder in elderly patients". Neuropsychobiology 54 (3): 152–9. doi:10.1159/000098650. PMID17230032.
Guerdjikova, Anna I.; Susan L. McElroy, Renu Kotwal, Jeffrey A. Welge, Erik Nelson, Katie Lake, David D' Alessio, Paul E. Keck Jr, James I. Hudson (2008). "High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial". Human Psychopharmacology: Clinical and Experimental 23 (1): 1–11. doi:10.1002/hup.899. PMID18058852
Malling, D.; Poulsen, M.; Søgaard, B. (2005). "The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects". British journal of clinical pharmacology 60 (3): 287–290. doi:10.1111/j.1365-2125.2005.02423.x. PMID16120067. edit